AMLX has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
AMLX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Amylyx Pharmaceuticals's Enterprise Value is $-237.9 Mil. Amylyx Pharmaceuticals's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was $10.7 Mil. Therefore, Amylyx Pharmaceuticals's EV-to-FCF for today is -22.28.
The historical rank and industry rank for Amylyx Pharmaceuticals's EV-to-FCF or its related term are showing as below:
During the past 5 years, the highest EV-to-FCF of Amylyx Pharmaceuticals was 87.46. The lowest was -23.17. And the median was -11.74.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
As of today (2024-04-30), Amylyx Pharmaceuticals's stock price is $1.905. Amylyx Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $0.700. Therefore, Amylyx Pharmaceuticals's PE Ratio for today is 2.72.
The historical data trend for Amylyx Pharmaceuticals's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Amylyx Pharmaceuticals Annual Data | |||||||||||
Trend | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | ||||||
EV-to-FCF | - | - | - | -11.61 | 58.96 |
Amylyx Pharmaceuticals Quarterly Data | |||||||||||||||
Dec19 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | |
EV-to-FCF | Get a 7-Day Free Trial | -11.61 | -11.10 | -12.12 | -16.76 | 58.96 |
For the Biotechnology subindustry, Amylyx Pharmaceuticals's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Amylyx Pharmaceuticals's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Amylyx Pharmaceuticals's EV-to-FCF falls into.
Amylyx Pharmaceuticals's EV-to-FCF for today is calculated as:
EV-to-FCF | = | Enterprise Value (Today) | / | Free Cash Flow (TTM) |
= | -237.914 | / | 10.678 | |
= | -22.28 |
Amylyx Pharmaceuticals's current Enterprise Value is $-237.9 Mil.
Amylyx Pharmaceuticals's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $10.7 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Amylyx Pharmaceuticals (NAS:AMLX) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Amylyx Pharmaceuticals's PE Ratio for today is calculated as:
PE Ratio | = | Share Price (Today) | / | Earnings per Share (Diluted) (TTM) |
= | 1.905 | / | 0.700 | |
= | 2.72 |
Amylyx Pharmaceuticals's share price for today is $1.905.
Amylyx Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.700.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Thank you for viewing the detailed overview of Amylyx Pharmaceuticals's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.
Joshua B Cohen | director, officer: Co-Chief Executive Officer | C/O AMYLYX PHARMACEUTICALS, INC., 43 THORNDIKE STREET, CAMBRIDGE MA 02141 |
Justin B. Klee | director, officer: Co-Chief Executive Officer | C/O AMYLYX PHARMACEUTICALS, INC., 43 THORNDIKE STREET, CAMBRIDGE MA 02141 |
Patrick D Yeramian | officer: Chief Medical Officer | 1815 PARKSIDE CIRCLE SOUTH, BOCA RATON FL 33486 |
James M Frates | officer: Chief Financial Officer | 88 SIDNEY ST, CAMBRIDGE MA 021394136 |
Karen Firestone | director | C/O AMYLYX PHARMACEUTICALS, INC., 43 THORNDIKE ST., CAMBRIDGE MA 02141 |
Gina Mazzariello | officer: Chief Legal Officer | C/O AMYLYX PHARMACEUTICALS, INC., 43 THORNDIKE STREET, CAMBRIDGE MA 02141 |
Morningside Venture Investments Ltd | 10 percent owner | MCCARTHY LEGAL SERVICES, 1188 CENTRE STREET, NEWTON CENTRE MA 02459 |
Milne George M Jr | director | |
Margaret Olinger | officer: Chief Commercial Officer | C/O AMYLYX PHARMACEUTICALS, INC., 43 THORNDIKE STREET, CAMBRIDGE MA 02141 |
Viking Global Investors Lp | 10 percent owner | 600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901 |
Dragsa 96 Llc | 10 percent owner | 55 RAILROAD AVE., GREENWICH CT 06830 |
Als Invest 1 B.v. | 10 percent owner | EERSTE WELERINGDWARSSTRAAL 54E, 1017 TP, AMSTERDAM P7 1017 |
Isaac Cheng | director | C/O ATEA PHARMACEUTICALS, INC., 125 SUMMER STREET, BOSTON MA 02110 |
Mvil, Llc | 10 percent owner | 22ND FLOOR HANG LUNG CENTRE, 2-20 PATERSON STREET, CAUSEWAY BAY K3 00000 |
Ole Andreas Halvorsen | 10 percent owner | 600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901 |
From GuruFocus
By Business Wire • 08-10-2023
By Business Wire • 10-10-2023
By Business Wire • 11-02-2023
By Business Wire Business Wire • 05-11-2023
By GuruFocus Research GuruFocus Editor • 05-19-2023
By Business Wire • 08-03-2023
By Business Wire • 07-12-2023
By Business Wire • 10-02-2023
By Business Wire Business Wire • 06-15-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.